Eli Lilly and Company (NYSE:LLY) Shares Climb 3.6% - Still a Buy?

Key Points

• Eli Lilly shares rose 3.6% to about $1,285.61 after Goldman Sachs raised its price target to $1,413 and reiterated a Buy rating, citing expected earnings strength and continued Mounjaro and Zepbound growth.
• GLP-1 treatments remain Lilly’s main growth catalyst. Potential European approval for oral obesity drug Foundayo, positive pediatric Omvoh data and a possible $1.1 billion AI drug-delivery partnership add further pipeline opportunities.
• Valuation and execution risks remain significant ahead of the Oct. 29 earnings report. Lilly trades at a premium valuation and faces competition, pricing pressure and legal risks, although analysts maintain a consensus “Moderate Buy” rating with a $1,314.93 target price.

Eli Lilly and Company (NYSE:LLY - Get Free Report) traded up 3.6% during mid-day trading on Tuesday. The company traded as high as $1,311.75 and last traded at $1,285.6060. Approximately 2,956,271 shares changed hands during mid-day trading, an increase of 0% from the average session volume of 2,947,191 shares. The stock had previously closed at $1,240.34.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs raised its price target to $1,413 from $1,371 and reiterated a Buy rating. The firm reportedly expects Eli Lilly to exceed third-quarter earnings estimates and increase its outlook, supported by stronger international Mounjaro growth and rising Zepbound volume through Medicare’s GLP-1 Bridge program. Eli Lilly Gains 4.6% as Goldman Sachs Lifts Price Target to $1,413
• Positive Sentiment: GLP-1 momentum remains the primary growth catalyst. Investors continue to view Mounjaro and Zepbound as drivers of rapid revenue and earnings growth, while Lilly’s oral obesity treatment Foundayo is reportedly nearing European approval and is expected by Bank of America to gain market share. LLY Stock Hits New Record Ahead of Q3 Earnings
• Positive Sentiment: Positive pediatric ulcerative-colitis data could expand Omvoh’s addressable market. In the Phase 3 SHINE-2 study, 81% of patients responded after induction, and half of responders ages 6–17 achieved clinical remission at Week 52. Lilly plans to submit the results to regulators for a potential label expansion. Lilly's Omvoh Meets Primary Endpoint
• Positive Sentiment: A new drug-delivery collaboration adds pipeline optionality. Lilly agreed to a potential $1.1 billion deal with Metis TechBio for AI-enabled drug-delivery technology. Metis TechBio Inks Deal With Eli Lilly
• Neutral Sentiment: Earnings are the next major test. Lilly reports third-quarter results on Oct. 29. The stock’s premium valuation and record-high level increase the importance of a meaningful earnings and guidance beat.
• Negative Sentiment: Investors continue to monitor valuation, competition and legal risks. Lilly trades at a substantial premium, faces potential pricing pressure from Novo Nordisk, and is defending a Pennsylvania lawsuit alleging insulin price inflation. These issues could limit upside if GLP-1 growth or future guidance disappoints. Why Is Eli Lilly Being Sued Over Alleged Insulin Price Inflation?

Analysts Set New Price Targets

Several research analysts have commented on the company. The Goldman Sachs Group restated a "buy" rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a report on Tuesday. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a report on Thursday, October 8th. Wall Street Zen downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday. Citigroup raised their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Finally, Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the company a "buy" rating in a research note on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,314.93.

Eli Lilly and Company Trading Up 3.6%

The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.21 trillion, a P/E ratio of 43.14, a price-to-earnings-growth ratio of 1.67 and a beta of 0.46. The company has a 50-day moving average price of $1,180.34 and a 200 day moving average price of $1,111.84.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the company earned $6.31 earnings per share. The firm's revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts forecast that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by insiders.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. Integrity Financial Corp WA grew its holdings in shares of Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock worth $767,000 after purchasing an additional 8 shares during the last quarter. Willner & Heller LLC increased its stake in shares of Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company's stock valued at $1,100,000 after buying an additional 9 shares during the period. Aspiring Ventures LLC raised its holdings in Eli Lilly and Company by 3.7% in the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company's stock valued at $306,000 after buying an additional 9 shares during the last quarter. Wealthspan Partners LLC raised its holdings in Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company's stock valued at $2,543,000 after buying an additional 9 shares during the last quarter. Finally, Navigoe LLC raised its holdings in Eli Lilly and Company by 8.7% in the 2nd quarter. Navigoe LLC now owns 113 shares of the company's stock valued at $135,000 after buying an additional 9 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.